Korean J Gastroenterol.
2006 Jan;47(1):15-21.
A Randomized, Prospective, Comparative, Multicenter Study of Rabeprazole and Ranitidine in the Treatment of Reflux Esophagitis
- Affiliations
-
- 1Department of Internal Medicine, Chungnam National University College of Medicine, Chungnam, Korea. jeonghy@cnu.ac.kr
- 2Department of Prevention Medicine, Chungnam National University College of Medicine, Chungnam, Korea.
- 3Department of Internal Medicine, Chungbuk National University College of Medicine, Chungbuk, Korea.
- 4Department of Internal Medicine, Soonchunhyang University Cheonan College of Medicine, Cheonan, Korea.
- 5Department of Internal Medicine, Daejeon St Mary's Hospital, Catholic University of Korea, Daejeon, Korea.
- 6Department of Internal Medicine, Eulji University of Medicine, Seoul, Korea.
- 7Department of Internal Medicine, Sun General Hospital, Daejeon, Korea.
Abstract
- BACKGROUND/AIMS: This study was done to evaluate the efficacy of rabeprazole (proton-pump-inhibitor) and ranitidine (H2-receptor antagonist) in the symptom relief and treatment of erosive esophagitis diagnosed by endoscopy. METHODS: A total of 110 patients with typical gastroesophageal reflux disease (GERD) symptoms were enrolled in this multicenter study. They were randomized into rabeprazole group (53 patients) and ranitidine group (57 patients) respectively. The patients in rabeprazole group were given 10 mg of rabeprazole and ranitidine group received 300 mg of ranitidine before breakfast and dinner for 8 weeks. After the end of treatment, we evaluated the endoscopic healing rate of reflux esophagitis and symptomatic improvement. RESULTS: After 8 weeks of treatment, rabeprazole group showed significantly higher complete endoscopic cure rate than ranitidine group (86.8% [46/53] vs. 57.9% [33/57], p=0.001) and higher symptomatic improvement of heartburn (91.2% [31/34] vs. 76.2% [32/42], p=0.085), especially in the first 7 days (76.7% vs. 45.3%, p=0.008). Also, rabeprazole group showed significantly higher improvement of regurgitation symptom than ranitidine group (100% [35/35] vs. 83% [39/47], p=0.009). Both group showed no differences in the improvement of chest pain and globus sensation. All the adverse events (rabeprazole group 4 events vs. ranitidine group 3 events) were mild and there was no abnormality in laboratory test. CONCLUSIONS: In patients with GERD, rabeprazole 10 mg b.i.d. is superior to ranitidine 300 mg b.i.d. in healing of reflux esophagitis and resolving typical GERD symptoms. Rabeprazole is an effective and well-tolerated drug for GERD treatment.
Keyword
MeSH Terms
-
2-Pyridinylmethylsulfinylbenzimidazoles
Adult
Anti-Ulcer Agents/*therapeutic use
Benzimidazoles/*therapeutic use
Esophagitis, Peptic/*drug therapy
Female
Histamine H2 Antagonists/*therapeutic use
Humans
Male
Middle Aged
Omeprazole/*analogs & derivatives/therapeutic use
Proton Pumps/*antagonists & inhibitors
Proton-Translocating ATPases/therapeutic use
Ranitidine/*therapeutic use
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Randomized, Comparative Study of Rabeprazole vs. Ranitidine Maintenance Therapies for Reflux Esophagitis: Multicenter Study
- The Role of Helicobacter Pylori Infection in Reflux Esophagitis
- Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants
- The Comparative Study on the Efficacy of Ranitidine and Rabeprazole in Reflux Laryngitis
- Cost-effectiveness analysis of proton pump inhibitors and ranitidine in the treatment of gastroesophageal reflux disease
